A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2<sup>+</sup> Solid Cancer

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2<sup>+</sup> Solid Cancer

The efficacy of CD19-specific CAR T cells in the treatment of leukemia/lymphoma relies, at least in part, on the unique properties of the particular CAR and the presence of healthy B cells that enhance the target cell lysis and cytokine secretion through repetitive stimulation. Here, we report to ap...

Full description

Bibliographic Details
Main Authors: Andreas A. Hombach, Christine Ambrose, Roy Lobb, Paul Rennert, Hinrich Abken
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Cells
Subjects:
chimeric antigen receptor
ErbB2 (Her2/neu)
herceptin
scFv fusion protein
CD19
Online Access:https://www.mdpi.com/2073-4409/12/2/248

Similar Items

Similar Items